Pharmaceutical composition for use in prevention or treatment of cognitive impairment
Benzoic acid or benzoate salts effectively improve cognitive function in long COVID patients by addressing neuroinflammation, providing a safer and more effective treatment for cognitive impairment.
Patent Information
- Application Number
- JP2025133679
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-09
- Filing Date
- 2025-08-08
- Publication Date
- 2026-02-24
AI Technical Summary
There is an urgent need for safer and more effective treatments for cognitive impairment associated with long COVID-19, as common practices have shown limited effectiveness and noninvasive brain stimulation technologies have inconsistent results with potential symptom recurrence.
Administering benzoic acid or a benzoate salt, such as sodium benzoate, to subjects in effective amounts ranging from 200 mg/day to 3000 mg/day, one to four times daily, for a period of one month to one year, to prevent or treat cognitive impairment caused by COVID-induced microglial activation, systemic inflammation, or neuroinflammation.
The treatment with benzoic acid or benzoate salts demonstrates improved cognitive function in long COVID patients, as shown by a decrease in Alzheimer's Disease Assessment Scale-Cognitive Subscale scores, with a favorable safety profile and no adverse events reported.